Pharvaris (PHVS) Operating Expenses (2025 - 2026)
Pharvaris posted quarterly Operating Expenses of -$51.8 million for Q1 2026, down 16.8% year-on-year from -$62.3 million in Q1 2025, and down 16.8% on a QoQ basis from -$44.4 million in Q1 2025.
Pharvaris (PHVS) has 2 years of Operating Expenses data on file, last reported at -$51.8 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Expenses fell 16.8% year-over-year to -$51.8 million; the trailing twelve-month figure through Mar 2026 stood at -$96.2 million (down 116.8% YoY), and the FY2025 full-year result was $191.9 million, up 21.68% from the prior year.
- Operating Expenses for Q1 2026 stood at -$51.8 million, down from -$44.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at -$44.4 million in Q1 2025 and bottomed at -$51.8 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 898.54 Mn |
| 10 | Pharvaris | 267.74 Mn | -73.74 Mn | - | -51.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.83 Mn |
| Mar 31, 2025 | -44.38 Mn |